New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

33

Ipsen snags Epizyme and cancer portfolio for a cool $247 million

“We expect that this acquisition and Ipsen’s commitment to invest in the oncology space will ensure our epigenetic pipeline continues to advance in a way we could not have done on our own to bring transformative cancer therapies to patients in need,” Bogle said in a statement,” company CEO David Loew said in a statement.